EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes

Shun Nakamura iD, Yukihiro Tanimura, Risa Nomura, Hiroshi Suzuki, Kouki Nishikawa, Akiko Kamegawa iD, Nobutaka Numoto iD, Atsushi Tanaka iD, Shigeru Kawabata iD, Shoichi Sakaguchi iD, Akino Emi, Youichi Suzuki iD und 1 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2413465122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Shun Nakamura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Structural Physiology Laboratory, Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku,…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Peptides, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research (A).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogen mutations present an inevitable and challenging problem for therapeutics and the development of mutation-tolerant anti-infective drugs to strengthen global health and combat evolving pathogens is urgently needed. While spike proteins on viral surfaces are attractive targets for preventing viral entry, they mutate frequently, making it difficult to develop effective therapeutics. Here, we used a structure-guided strategy to engineer an inhibitor peptide against the SARS-CoV-2 spike, called CeSPIACE, with mutation-tolerant and potent binding ability against all variants to enhance affinity for the invariant architecture of the receptor-binding domain (RBD). High-resolution structures of the peptide complexed with mutant RBDs revealed a mechanism of mutation-tolerant inhibition. CeSPIACE bound major mutant RBDs with picomolar affinity and inhibited infection by SARS-CoV-2 variants in VeroE6/TMPRSS2 cells (IC 50 4 pM to 13 nM) and demonstrated potent in vivo efficacy by inhalation administration in hamsters. Mutagenesis analyses to address mutation risks confirmed tolerance against existing and/or potential future mutations of the RBD. Our strategy of engineering mutation-tolerant inhibitors may be applicable to other infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2PeptidesAntiviral AgentsCOVID-19 Drug TreatmentAnimalsChlorocebus aethiopsMutationVero CellsHumansCOVID-19Protein EngineeringCricetinaeVirus Internalization

Stichwörter der Autor:innen

SARS-CoV-2peptide engineeringspikestructural biology

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2PeptidesAntiviral Agents

Autor:innen und Institutionen

  • Cellular and Structural Physiology Laboratory, Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Tokyo 113-8510, Japan.
  • CeSPIA Inc., Taisei Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan.
  • International Center for Structural Biology, Research Institute for Interdisciplinary Science, Okayama University, Kita-ku, Okayama 700-8530, Japan.
  • Division of Research Animal Laboratory and Translational Medicine, Research and Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.
  • Department of Pathology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.
  • Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.

ORCID-Profile: Shun Nakamura, Akiko Kamegawa, Nobutaka Numoto, Atsushi Tanaka, Shigeru Kawabata, Shoichi Sakaguchi, Youichi Suzuki

Förderung

  • Japan Agency for Medical Research and Development (AMED)
  • Grants-in-Aid for Scientific Research (A)

Zitieren

APA

Nakamura, S., Tanimura, Y., Nomura, R., Suzuki, H., Nishikawa, K., Kamegawa, A., Numoto, N., Tanaka, A., Kawabata, S., Sakaguchi, S., Emi, A., Suzuki, Y., & Fujiyoshi, Y. (2025). Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2413465122

Vancouver

Nakamura S, Tanimura Y, Nomura R, Suzuki H, Nishikawa K, Kamegawa A, et al. Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2413465122

BibTeX
@article{Nakamura2025,
  author = {Nakamura, Shun and Tanimura, Yukihiro and Nomura, Risa and Suzuki, Hiroshi and Nishikawa, Kouki and Kamegawa, Akiko and Numoto, Nobutaka and Tanaka, Atsushi and Kawabata, Shigeru and Sakaguchi, Shoichi and Emi, Akino and Suzuki, Youichi and Fujiyoshi, Yoshinori},
  title = {Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2413465122}
}
Kostenlos starten →